to determine the maximum tolerated dose ( mtd ) of trimetrexate glucuronate in combination with cyclophosphamide in patients with metastatic or inoperable nonsmall cell lung cancer ( nsclc ) , trimetrexate in dosages ranging from 3 to 13.5 mg/m2/day was administered intravenously ( iv ) to 27 patients for 5 days in combination with cyclophosphamide , 600 mg/m2 , on day 1 .
C0077209
trimetrexate glucuronate
C0085176
trimetrexate